Strategic Research Centre for Mucosal Immuniobiology and Vaccines
- Reference number
- A3 05:194
- Start and end dates
- 060101-121231
- Amount granted
- 46 000 000 SEK
- Administrative organization
- Göteborg University
- Research area
- Life Sciences
Summary
Vaccines constitute one of the most cost-effective preventive measures against illness and death. Moreover, needle-free mucosal vaccination is found high on the list of priorities for the WHO and other health organisations. International organisations and industries are therefor looking for strategic research centres to invest in programs for vaccine development. Göteborg University has a strong research tradition in the field of mucosal immunology and vaccine development. MIVAC scientists are participating actively in programmes for prevention of diarrheal diseases, TB, HIV and malaria. The centre will address completely new concepts for vaccine construction and expand our understanding of the interactions between innate and adaptive immunity at mucosal membranes. The overall goal is to take basic findings and patent-protected discoveries from the bench to clinical practice and industrial exploitation. MIVAC spans several faculties and has access to the full services of the laboratory for Clinical Immunology/Laboratory Medicine at Sahlgren’s University Hospital as well as to the facilities of collaborating clinical units in e.g. gastroenterology, infectious diseases, pulmonary medicine and surgery.